Oxeia Biopharmaceuticals is a clinical stage company developing ghrelin as a treatment for concussions and other neurotrauma indications. This is a phase 2 ready program with nearly 350 patient safety database and cGMP supply. Oxeia expects to have clinical data within 18 months of trial start. US Unmet need: > 3 M concussions per yr.
Oxeia Biopharmaceuticals, Inc.Arash Sani2018-02-13T08:56:41-08:00